Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Boston Scientific Closes $1.7B Baylis Medical Deal - Medical Product Outsourcing
Financial & Business, OEM News

Boston Scientific Closes $1.7B Baylis Medical Deal

Baylis platforms bolster Boston Scientific's existing electrophysiology and structural heart offerings.

Boston Scientific has closed the $1.75 billion deal for interventional cardiology company Baylis Medical. Baylis offers transseptal access technologies as well as guidewires, sheaths, and dilators used in catheter-based left-heart surgeries. The deal was first announced in October.
 
“The close of this acquisition allows Boston Scientific to integrate the Baylis platforms with our existing electrophysiology and structural heart offerings, further strengthening our position within the highest growth cardiology markets,” Boston Scientific executive VP and president of Cardiology Joe Fitzgerald told the press. “We are now the only company to pair a comprehensive access portfolio with existing left-heart therapies such as left atrial appendage closure and atrial fibrillation ablation, providing physicians with a complete toolbox to treat patients with safety, efficacy and efficiency.”
 
Boston Scientific expects the transaction to be about one cent accretive to earnings per share in 2022. The deal is expected to be less accretive on a GAAP basis this year.

Add us as a preferred source on Google

Get the latest Medical Product Outsourcing news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters